Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics

Theranostics

Volumn 4, Issue 6, 2014, Pages 660-677

  Muthu, Madaswamy S ^a,b   Leong, David Tai ^a   Mei, Lin ^c   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BANARAS HINDU UNIVERSITY   (India)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Cancer nanotechnology; Drug targeting; Molecular biomaterials; Molecular imaging; Oral chemotherapy; Pharmaceutical nanotechnology

Indexed keywords

CARBON NANOTUBE; DENDRIMER; DIAGNOSTIC AGENT; GOLD NANOPARTICLE; LIGAND; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCARRIER; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; NANOMATERIAL;

AUTOPHAGY; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; HOST RESISTANCE; HUMAN; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; NANOTHERANOSTICS; NONHUMAN; PROGNOSIS; REVIEW; SYSTEMIC CIRCULATION; THERANOSTICS; ANIMAL; DIAGNOSTIC USE; PROCEDURES;

ANIMALS; HUMANS; NANOMEDICINE; NANOSTRUCTURES;

EID: 84902529384     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8698     Document Type: Review

References (153)

1. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond). 2008; 3(2): 137-140.
2. Deveza L, Choi J, Yang F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics. 2012; 2(8):801-814.
3. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010; 62(11): 1052-1063.
4. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012; 2(1):3-44.
5. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62(11):1064-79.
6. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011; 1:102-126.
7. Feng SS. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine (Lond). 2006 Oct;1(3):297-309.
8. Muthu MS, Feng SS. Theranostic liposomes for cancer diagnosis and treatment:current development and pre-clinical success. Expert Opin Drug Deliv. 2013; 10(2):151-155.
9. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond). 2009; 4(1):105-118.
10. Muthu MS, Rajesh CV, Mishra A, et al. Stimulus responsive targeted nanomicelles for effective cancer therapy. Nanomedicine (Lond). 2009; 4(6):657-667.
11. Zhao J, Mi Y, Feng SS. siRNA based nanomedicine. Nanomedicine (Lond). 2013; 8(6): 859-862.
12. Mei L, Zhang Z, Zhao L, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Del Rev. 2013; 65(6): 880-890.
13. Smith BA, Smith BD. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem. 2012; 23(10): 1989-2006.
14. Lammers T, Aime S, Hennink WE, et al. Theranostic nanomedicine. Acc Chem Res. 2011; 44(10): 1029-1038.
15. Caldorera-Moore ME, Liechty WB, Peppas NA. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res. 2011; 44(10): 1061-1070.
16. Xu C, Zhao W. Nanoparticle-based monitoring of stem cell therapy. Theranostics. 2013; 3(8):616-617.
17. Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011; 44(10): 1114-1122.
18. Tan YF, Chandrasekharan P, Maity D, et al. Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials. 2011; 32(11): 2969-2978.
19. Zhao L, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in Vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci. 2010; 99(8): 3552-3560.
20. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D, L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials. 2006; 27(10): 2285-2291.
21. Santra S. The potential clinical impact of quantum dots. Nanomedicine (Lond). 2012; 7(5): 623-626.
22. Yong KT, Wang Y, Roy I, et al. Preparation of quantum dot/drug nanoparticle formulations for traceable targeted delivery and therapy. Theranostics. 2012; 2(7):681-694.
23. McCarthy JR, Jaffer FA, Weissleder R. A macrophage- targeted theranostic nanoparticle for biomedical applications. Small. 2006; 2(8-9): 983-987.
24. Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012; 2(11):1040-1053.
25. Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics. 2012; 2(5):424-426.
26. Choi KY, Liu G, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale. 2012; 4(2): 330-342.
27. Win KY, Feng SS. Effect of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26(15): 2713-2722.
28. Zhang S, Li J, Lykotrafitis G, et al. Size-dependent endocytosis of nanoparticles. Adv Mater. 2009; 21 (4): 419-424.
29. Decuzzi P, Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials. 2007; 28(18):2915-2922.
30. Tan GR, Feng SS, Leong DT. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials. 2014; 35 (9): 3044-3051.
31. Gan CW, Chien S, Feng SS. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des. 2010; 16 (21): 2308-2320.
32. Zhao J, Feng SS. Effects of PEG tethering chain length of Vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs. Biomaterials. 2014; 35 (10): 3340-3347.
33. Lammers T, Ulbrich K. HPMA copolymers: 30 years of advances. Adv Drug Del Rev. 2010; 62 (2): 119-121.
34. Allmeroth M, Moderegger D, Gündel D, et al. PEGylation of HPMA-based block copolymers enhances tumor accumulation in vivo: A quantitative study using radiolabeling and positron emission tomography. J Control Release. 2013; 172 (1): 77-85.
35. Kopecek J, Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Del Rev. 2010; 62(2): 122-149.
36. Nakamura H, Etrych T, Chytil P, et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl) methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release. 2014; 174:81-87.
37. Vasey PA, Kaye SB, Morrision R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]:first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer research campaign phase I/II committee. Clin Cancer Res. 1999; 5 (1): 83-94.
38. Borgman MP, Coleman T, Kolhatkar RB, et al. Tumor-targeted HPMA copolymer-( RGDfk)-(CHX-A"-DTPA) conjugates show increased kidney accumulation. J Control Release. 2008; 132(3): 193-199.
39. Yuan J, Zhang H, Kaur H, et al. Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA-64Cu copolymer targeting tumor angiogenesis:tumor localization visualized by positron emission tomography. Mol Imaging. 2013; 12(3): 1-10.
40. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel:effects of the emulsifier and drug loading ratio. Pharm Res. 2003; 20(11):1864-1872.
41. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012; 33(19): 4889-4906.
42. Hu CM, Fang RH, Luk BT, et al. Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale. 2014; 6 (1): 65-75.
43. Luk BT, Fang RH, Zhang L. Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics. 2012; 2(12):1117-1126.
44. Moore T, Chen H, Morrison R, et al. Nanotechnologies for noninvasive measurement of drug release. Mol Pharm. 2014; 11 (1): 24-39.
45. Vijayakumar MR, Muthu MS, Singh S. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines:versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opin Drug Deliv. 2013; 10(4): 529-543.
46. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70 (1-2): 1-20.
47. Svenson S. Theranostics: Are we there yet? Mol Pharm. 2013; 10 (3): 848-856.
48. Mok H, Park TG. Hybrid polymeric nanomaterials for siRNA delivery and imaging. Macromol Biosci. 2012; 12 (1): 40-48.
49. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53(2):283-318.
50. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26 (18): 3995-4021.
51. Yen SK, Padmanabhan P, Selvan ST. Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery. Theranostics. 2013; 3(12):986-1003.
52. Li L, Jiang W, Luo K, et al. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. Theranostics. 2013; 3(8):595-615.
53. Huang G, Chen H, Dong Y, et al. Superparamagnetic iron oxide nanoparticles:amplifying ROS stress to improve anticancer drug efficacy. Theranostics. 2013; 3(2):116-126.
54. Yoo D, Lee JH, Shin TH, et al. Theranostic magnetic nanoparticles. Acc Chem Res. 2011; 44(10): 863-874.
55. Clemente-Casares X, Santamaria P. Nanomedicine in autoimmunity. Immunol Lett. 2014; 158 (1-2): 167-174.
56. Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008; 108 (6): 2064-2110.
57. Mornet S, Vasseur S, Fabien Grasset et al. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem. 2004; 14: 2161-2175.
58. Zhang X, Dong Y, Zeng X et al. The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment. Biomaterials. 2014; 35 (6): 1932-1943.
59. Pan J, Liu Y, Feng SS. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond). 2010; 5(3): 347-360.
60. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007; 13(3): 372-377.
61. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1): 161-177.
62. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Del Rev. 2001; 47 (2-3): 165-196.
63. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Del Rev. 2004; 56 (9): 1257-1272.
64. Muller RH, Rühl D, Runge S, et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997; 14(4): 458-462.
65. Singh I, Swami R, Khan W et al. Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin Drug Deliv. 2014; 11(2):211-219.
66. Shuhendler AJ, Prasad P, Leung M, et al. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012; 1(5):600-608.
67. Bae KH, Lee JY, Lee SH, et al. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv Healthc Mater. 2013; 2(4):576-584.
68. Fahmy TM, Fong PM, Park J, et al. Nanosystems for simultaneous imaging and drug delivery to T Cells. AAPS J. 2007; 9(2): E171-E180.
69. Bosman AW, Janssen HM, Meijer EW. About dendrimers: Structure, physical properties, and applications. Chem Rev. 1999; 99 (7): 1665-1688.
70. Frechet JM. Functional polymers and dendrimers - reactivity, molecular architecture, and interfacial energy. Science. 1994; 263 (5154): 1710-1715.
71. Li Y, Cheng Y, Xu T. Design, synthesis and potent pharmaceutical applications of glycodendrimers; a mini review. Curr Drug Discov Technol. 2007; 4(4):246-254.
72. Jansen JF, de Brabander-van den Berg EM, Meijer EW. Encapsulation of guest molecules into a dendritic box. Science. 1994; 266 (5188): 1226-1229.
73. Grünwald GK, Vetter A, Klutz K et al. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med. 2013; 54(8): 1450-1457.
74. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release. 2008; 130(2): 107-114.
75. Taratula O, Schumann C, Naleway MA, et al. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image guided drug delivery and photodynamic therapy. Mol Pharm. 2013; 10(10): 3946-3958.
76. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998; 16(7):307-321.
77. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2): 145-160.
78. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med. 2002; 6(4): 465-474.
79. Grange C, Geninatti-Crich S, Esposito G, et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin- containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res. 2010; 70(6): 2180-2190.
80. Nie Y, Ji L, Ding H, et al. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics. 2012; 2(11):1092-1103.
81. Leung SJ, Romanowski M. Light-activated content release from liposomes. Theranostics. 2012; 2(10):1020-1036.
82. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145-160.
83. Papahadjopoulos D, Allen TM, Gabizon A et al. Sterically stabilized liposomes - improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991; 88(24): 11460-11464.
84. Al-Jamal WT, Kostarelos K. Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011; 44(10): 1094-1104.
85. Al-Jamal WT, Al-Jamal KT, Tian B, et al. Lipid-quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS Nano. 2008; 2(3): 408-418.
86. Muthu MS, Feng SS. Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond). 2010; 5(7): 1017-1019.
87. Muthu MS, Kulkarni SA, Xiong J et al. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm 2011; 421(2): 332-340.
88. Muthu MS, Kulkarni SA, Raju A, et al. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012; 33(12): 3494-3501.
89. Wen CJ, Zhang LW, Al-Suwayeh SA, et al. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine. 2012; 7: 1599-611.
90. Wen CJ, Sung CT, Aljuffali IA, et al. Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes. Nanotechnology. 2013; 24(32): 325101.
91. Mahmud A, Xiong XB, Aliabadi HM, et al. Polymeric micelles for drug targeting. J Drug Target. 2007; 15(9): 553-584.
92. Sawant RR, Jhaveri AM, Koshkaryev A, et al. Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma. Mol Pharm. 2014; 11(2): 375-381.
93. Kataoka, K, Harada, A, Nagasaki Y. Block copolymer micelles for drug delivery:design, characterization and biological significance. Adv Drug Deliv Rev. 2001; 47(1):113-131.
94. Vriezema DM, Comellas AM, Elemans JA, et al. Self-assembled nanoreactors. Chem Rev. 2005; 105 (4): 1445-1489.
95. Kumar R, Kulkarni A, Nagesha DK, et al. In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer. Theranostics. 2012; 2(7):714-722.
96. Liu L, Yong KT, Roy I, et al. Bioconjugated pluronic triblock-copolymer micelle-encapsulated quantum dots for targeted imaging of cancer: in vitro and in vivo studies. Theranostics. 2012; 2(7):705-713.
97. Mi Y, Liu Y, Feng SS. Formulation of docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32(16):4058-4066.
98. Torchilin VP, Lukyanov AN, Gao Z, et al. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003; 100(10): 6039-6044.
99. Savic R, Luo LB, Eisenberg A, et al. Miceller nanocontainers distribute to defined cytoplasmic organelles. Science. 2003; 300(5619): 615-618.
100. Moghimi SM, Hunter AC, Murray JC, et al. Cellular distribution of nonionic micelles. Science. 2004; 303(5658): 626-628.
101. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001; 72(1-3):191-202.
102. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008; 108(2):241-250.
103. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007; 108(12):2009-2014.
104. Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol. 2010; 21(2): 382-388.
105. Muthu MS, Kulkarni SA, Liu Y, et al. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond). 2012; 7(3):353-364.
106. Zhao J, Mi Y, Feng SS. Targeted co-delivery of docetaxel and siPlk1 by herceptin- conjugated vitamin E TPGS based immunomicelles. Biomaterials. 2013; 34(13):3411-3421.
107. Kutty RV, Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials. 2013; 34(38):10160-10171.
108. Chandrasekharan P, Maity D, Yong CX, et al. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles- superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials. 2011; 32(24): 5663-5672.
109. Kim KS, Park SJ, Lee MY, et al. Gold half-shell coated hyaluronic acid- doxorubicin conjugate micelles for theranostic applications. Macromol Res. 2012; 20(3): 277-282.
110. Chen H, Zhang X, Dai S, et al. Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy. Theranostics. 2013; 3(9):633-49.
111. Xiao Y, Hong H, Matson VZ, et al. Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET Imaging. Theranostics. 2012; 2(8):757-768.
112. Rengan AK, Jagtap M, De A, et al. Multifunctional gold coated thermo- sensitive liposomes for multimodal imaging and photo-thermal therapy of breast cancer cells. Nanoscale. 2013; 6(2):916-923.
113. Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004; 104(1): 293-346.
114. Link S, El-Sayed MA. Shape and size dependence of radiative, non-radiative and photothermal properties of gold nanocrystals. Int Rev In Physical Chemistry. 2002; 19 (3): 409-453.
115. Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005; 1(3): 325-327.
116. Kumar R, Korideck H, Ngwa W, et al. Third generation gold nanoplatform optimized for radiation therapy. Transl Cancer Res. 2013; 2(4): doi:10.3978/j.issn.2218-676X.2013.07.02.
117. Han G, Martin CT, Rotello VM, et al. Stability of gold nanoparticle-bound DNA toward biological, physical, and chemical agents. Chem Biol Drug Des. 2006; 67(1): 78-82.
118. Lee SM, Kim HJ, Kim SY, et al. Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials. 2014; 35(7):2272-2282.
119. Heo DN, Yang DH, Moon HJ, et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials. 2012; 33(3): 856-866.
120. Chen WH, Xu XD, Jia HZ, et al. Therapeutic nanomedicine based on dual- intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials. 2013; 34(34): 8798-8807.
121. Liu Z, Liang XJ: Nano-carbons as theranostics. Theranostics. 2012; 2(3): 235-237.
122. Baughman RH, Zakhidov AA, De Heer WA. Carbon nanotubes - the route toward applications. Science. 2002; 297 (5582): 787-792.
123. Fubini B, Ghiazza M, Fenoglio I. Physio-chemical features of engineered nanoparticles relevant to their toxicity. Nanotoxicology. 2010; 4: 347-363.
124. Porter AE, Gass M, Muller K et al. Direct imaging of single-walled carbon nanotubes in cells. Nat Nanotechnol. 2007; 2:713-717.
125. McDevitt MR, Chattopadhyay D, Kappel BJ, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nuclear Med. 2007; 48(7): 1180-1189.
126. Yang K, Feng L, Shi X, et al. Nano-graphene in biomedicine:theranostic applications. Chem Soc Rev. 2013; 42(2): 530-547.
127. Shen H, Zhang L, Liu M, et al. Biomedical applications of graphene. Theranostics. 2012; 2(3):283-294.
128. Chen Z, Ma L, Liu Y et al. Applications of functionalized fullerenes in tumor theranostics. Theranostics. 2012; 2(3):238-250.
129. Nerl HC, Cheng C, Goode AE, et al. Imaging methods for determining uptake and toxicity of carbon nanotubes in vitro and in vivo. Nanomedicine (Lond). 2011; 6 (5): 849-865.
130. Boncel S, Müller KH, Skepper JN et al. Tunable chemistry and morphology of multi-wall carbon nanotubes as a route to non-toxic, theranostic systems. Biomaterials. 2011; 32 (30): 7677-7686.
131. Robinson JT, Welsher K, Tabakman SM, et al. High performance in vivo near-IR (>1μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010; 3 (11): 779-793.
132. Das M, Datir SR, Singh RP, et al. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based a fluorescent and radiolabeled, methotrxate-folic acid-multiwalled carbon nanotube conjugate. Mol Pharm. 2013; 10 (7): 2543-2557.
133. Qin SY, Feng J, Rong L, et al. Theranostic GO-based nanohybrid for tumor induced imaging and potential combinational tumor therapy. Small. 2014; 10 (3): 599-608.
134. Muthu MS, Wilson B. Multifunctional radionanomedicine: a novel nanoplatform for cancer imaging and therapy. Nanomedicine (Lond). 2010; 5(2):169-171.
135. Bardhan R, Lal S, Joshi A, et al. Theranostic nanoshells: From probe design to imaging and treatment of cancer. Acc Chem Res. 2011; 44(10):936-946.
136. Muthu MS, Feng SS. Targeted nanomedicine for detection and treatment of circulating tumor cells. Nanomedicine (Lond). 2011; 6(4):579-581.
137. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011; 44(10): 875-882.
138. Zhu Y, Hong H, Xu ZP, et al. Quantum dot-based nanoprobes for in vivo targeted imaging. Curr Mol Med. 2013; 13(10):1549-1567.
139. Wu X, Tian F, Zhao JX, et al. Evaluating pharmacokinetics and toxicity of luminescent quantum dots. Expert Opin Drug Metab Toxicol. 2013; 9(10):1265-1277.
140. Tsukahara T, Haniu H. Cellular cytotoxic response induced by highly purified multi-wall carbon nanotubes in human lung cells. Mol Cell Biochem. 2011; 352(1-2): 57-63.
141. Yamashita K, Yoshioka Y, Higashisaka K,et al. Carbon nanotubes elicit DNA damage and inflammatory response relative to their size and shape. Inflammation. 2010; 33: 276-280.
142. Ge C, Meng L, Xu L,et al. Acute pulmonary and moderate cardiovascular responses of spontaneously hypertensive rats after exposure to single-wall carbon nanotubes. Nanotoxicology. 2012; 6(5): 526-542.
143. Muthu MS. Abdulla A, Pandey BL. Major toxicities of carbon nanotubes induced by reactive oxygen species: should we worry about the effects on the lungs, liver and normal cells? Nanomedicine (Lond). 2013; 8(6): 863-866.
144. Yang ST, Luo J, Zhou Q, et al. Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes. Theranostics. 2012; 2(3):271-282.
145. Mateo D, Morales P, Avalos A, et al. Oxidative stress contributes to gold nanoparticle-induced cytotoxicity in human tumor cells. Toxicol Mech Methods. 2014; 24(3): 161-172.
146. Yuan X, Setyawati MI, Leong DT, et al. Ultrasmall Ag+-rich nanoclusters as highly efficient nanoreservoirs for bacterial killing. Nano Res. 2013; doi:10.1007/s12274-013-0395-6. [Epub ahead of print].
147. Setyawati MI, Tay CY, Leong DT. Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway. Biomaterials. 2013; 34(38): 10133-10142.
148. Tay CY, Fang W, Setyawati MI, et al. Reciprocal response of human oral epithelial cells to internalized silica nanoparticles. Part Part Syst Charact. 2013; 30(9): 784-793.
149. Setyawati MI, Fang WR, Chia SL, et al. Nanotoxicology of common metal oxide based nanomaterials: their ROS-y and non-ROS-y consequences. Asia-Pacific J Chem Eng. 2013; 8(2):205-217.
150. Setyawati MI, Khoo PK, Eng BH, et al. Cytotoxic and genotoxic characterization of titanium Dioxide, gadolinium oxide and poly(lactic-co-glycolic acid) nanoparticles in human fibroblasts. J Biomed Mat Res Part A. 2013; 101(3):633-640.
151. Ng KW, Khoo PKS, Heng BC, et al. Cellular DNA damage response to zinc oxide nanoparticles hinges on the tumor suppressor p53 pathway. Biomaterials. 2011; 32(32):8218-8225.
152. Setyawati MI, Tay CY, Chia SL, et al. TiO2 nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat Commun. 2013; 4:1673, doi: 10.1038/ncomms2655. [Epub ahead of print].
153. Tay CY, Cai PQ, Setyawati MI, et al. Nanoparticles strengthen intracellular tension and retard cellular migration. Nano Lett. 2014; 14(1): 83-88.